Home › Funds › ADAR1 Capital Management, LLC › PTGX

ADAR1 Capital Management, LLC position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

ADAR1 Capital Management, LLC reported holding 960,863 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$117.8M, representing 6.52% of its reported portfolio and ranking #1 among its reported holdings. ADAR1 Capital Management, LLC has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)960.86K sh
Reported value held$117.78M
Portfolio Weight6.52%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's PTGX position evolved

ADAR1 Capital Management, LLC first disclosed a stake in PTGX in Q4 2023 at 200,859 shares (US$4.6M). The position peaked in Q2 2026 at 960,863 shares, worth US$117.8M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 960,863 shares valued at US$117.8M — a reduction of -33,256 shares quarter over quarter.. Notable position changes include a 291% increase in Q1 2024 (shares rose 20% over the following quarter), a 104% increase in Q2 2024 (shares rose 30% over the following quarter), a 612% increase in Q1 2025 (shares rose 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 200.86K $4.61M New
Q1 2024 785.65K $22.73M Add
Q2 2024 1.60M $55.58M Add
Q3 2024 981.29K $44.16M Reduce
Q4 2024 132.00K $5.10M Reduce
Q1 2025 939.67K $45.44M Add
Q2 2025 948.07K $52.40M Add
Q3 2025 989.18K $65.71M Add
Q4 2025 1.05M $91.63M Add
Q1 2026 994.12K $104.78M Reduce
Q2 2026 960.86K $117.78M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held PTGX?

ADAR1 Capital Management, LLC has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is ADAR1 Capital Management, LLC's current position in PTGX?

As of Q2 2026, ADAR1 Capital Management, LLC holds 960.86K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $117.78M, representing 6.52% of its reported portfolio and ranking #1.

Has ADAR1 Capital Management, LLC been buying or selling PTGX?

In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in PTGX. The position peaked in Q2 2026 at 960.86K shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.